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Background: Advanced glycation end products (AGE) are substances that can induce insulin resistance in
adipocyte, hepatocyte and muscle cells. This resistance correlates highly with cardiovascular disease and diabetic
complications. Acteoside (A), a phenylethanoid glycoside, is an active compound in several plants and traditional
herbal medicines. Acteoside, its structural isomer, isoacteoside (I), and their constituents, caffeic acid (C) and 3,4-
dihydroxyphenylethanol (D), were used in the study to investigate the inhibitory activity against AGE formations
in vitro.
Results: AGE formations were detected by anti-(Nε-(carboxymethyl)lysine (anti-CML), using bovine serum albumin
(BSA)/glucose (glc) and BSA/galactose (gal) as models, or by anti-argpyrimidine (anti-AP), using BSA/methylglyoxal
(MGO) as models. It was found that A, I, C, or D, each at 5 mM, could attenuate the CML formations detected by
ELISA in the BSA/gal model of a 3-day or 5-day reaction, and showed significant differences (P < 0.01 or P < 0.001)
compared to the control. However, these compounds showed a minor effect after a 7-day incubation. It was
also found that C or D could lower the CML formations in the BSA/glc model and showed significant differences
(P < 0.05 or P < 0.01) compared to the control after a 3-day, 5-day and 7-day reaction. It was found that A, I, C, or D,
each at 0.5 mM or 5 mM, could attenuate the AP formations in the BSA/MGO model of a 3-day reaction and showed
significant differences (P < 0.001) compared to the control.
Conclusions: The results suggest the potential anti-glycation activities of A and I in vitro may apply to cell models at
higher glucose concentrations or to diabetic animal models, and need further investigation.
Keywords: Acteoside; Advanced glycation endproducts; Argpyrimidine; Cafeic acid; Nε-(carboxymethyl)lysine;
3′,4′-dihydroxyphenylethanol; Isoacteoside; MethylglyoxalBackground
Acteoside (A) or its structural isomer of isoacteoside (I), a
phenylethanoid glycoside containing caffeic acid (C), 3′,4′-
dihydroxyphenylethanol (D), glucose, and rhammose, is
reported in many plants and herbal medicines. Among
these are Ligstrum purpurascens (Wong et al., 2001a,b),
Brandisia hancei (He et al. 2001),Veronica persica (Harput
et al. 2002), Pedicularis striata (Chen et al. 2002), Cistanche
salsa (Pu et al. 2003), Buddleja officinalis (Lee et al. 2005),* Correspondence: wchou@tmu.edu.tw
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in any medium, provided the original work is pCallicarpa dichotoma (Koo et al. 2005, 2006; Lee et al.
2006b), Clerodendron trichotomum (Lee et al. 2006a,
2007), Cistanche deserticola and Boschniakia rossica (Wu
et al. 2006), Scrophularia ningpoenis (Huang et al. 2008),
Rehmannia glutinosa (Li et al. 2006), and Harpagophytum
procumbens (Boje et al. 2003). Acteoside was reported to
exhibit antioxidant activities (Wong et al. 2001b) from
bitter tea (Ligstrum purpurascens), a popular beverage in
southern China. A and/or I were reported to have antioxi-
dant, anti-hemolytic activities, angiotensin converting
enzyme inhibitory activities, and anti-hypertensive activ-
ities using spontaneously hypertensive rats as models
(Chen et al. 2012). Koo et al. (2006) reported that A and
its aglycones effectively scavenge 1,1-diphenyl-2-picryl-
hydrazyl and nitric oxide in vitro. It was reported that Apen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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CAM-1 and vascular CAM-1 in human umbilical vein
endothelial cells (Chen et al. 2009). Acteoside also showed
protections against hydroxyl radical-induced oxidative
stress of bovine pulmonary endothelial cells (Chiou et al.
2004) and inhibitions to nitric oxide and TNF-α
productions throughg blocking AP-1 activations in
lipopolysaccharide-stimulated macrophages (Lee et al.
2005; Rao et al. 2009).
Reactive oxygen species (ROS)–mediated reactions
are closely associated with cardiovascular diseases,
neurodegenerative diseases and other chronic diseases
(Ames 1983; Gey 1990). In cells, respiratory chain reac-
tions and glycation processes are important sources of
ROS production. Glycation involves the nonenzymatic
modification of proteins (especially lysine or arginine
residues) through the reduction of sugars both in vitro
and in vivo, and their metabolized intermediates, such
as glyoxal or methylglyoxal (MGO). This induces the ir-
reversible formation of advanced glycation end products
(AGE), which may alter protein function and protein
degradation. AGE can bind to the receptor for AGE
(RAGE) on the membrane to elevate ROS productions
through activation of NADPH oxidase (Calcutt et al.
2009). AGE-RAGE interaction may overgenerate intra-
cellular ROS, which retards glucose uptake into adipo-
cytes and then induces monocyte inflammatory factor,
chemoattractant protein-1, to participate in the devel-
opment of obesity-related insulin resistance (Unoki and
Yamagishi 2008). Wu et al. (2011) reported that the
MGO-mediated glycated fetal bovine serum can in-
crease intracellular ROS and IL-1β expressions in THP-
1 monocytes, and TNF-α expressions in RAW264.7
macrophages. They proposed that MGO-mediated
glycated fetal bovine serum can cause oxidative and inflam-
matory injury of monocytes, macrophages and vascular
endothelial cells. Several AGEs have been identified, includ-
ing Nε-(carboxymethyl)lysine (CML), Nε-(carboxyethyl)
lysine, pyrraline, pentosidine, crossline, imidazolones,
glyoxal-lysine dimer, methylglyoxal-lysine dimer, Arg-
Lys imidazole, argpyrimidine (AP), etc. (Lapolla et al.
2006). It is suggested that AGE formations and accumu-
lations are correlated with cardiovascular disease, insu-
lin resistance and diabetic complications (Unoki and
Yamagishi 2008). In this study, A, I, and their constitu-
ents, C and D, were used to investigate the inhibitory
activity against AGE formations in vitro detected by
anti-CML, using bovine serum albumin (BSA)/glucose
(glc) and BSA/galactose (gal) as models or anti-AP
using BSA/MGO as models. BSA/glc and BSA/gal were
recognized as early stages of AGE formations; BSA/MGO
were recognized as middle stages of AGE formations
(Wu and Yen 2005). It was found that the potential
anti-glycation activities of A and I in vitro may apply tocell models at higher glucose concentrations or to dia-
betic animal models and needed further investigation.
Methods
Materials
Natural compounds of A and I were purchased from
Xinma Bio-Tech Co., LTD (purities > 98%, Shanghai,
China). The 3′,4′-dihydroxyphenylethanol was obtained
from Tokyo Chemical Industry Co., LTD (Tokyo, Japan).
Bovine serum albumin (BSA, 2 mg/ml, No. 23209) was
obtained from Thermo Fisher Scientific Inc. (Rockford,
IL). Gal, Glc, and caffeic acid were purchased from Sigma
Chemical Co. (St. Louis, MO). Anti-Nε-(carboxymethyl)
lysine (anti-CML) polyclonal antibody (ab27684) was
obtained from Abcam Inc. (Cambridge, MA), and anti-
argpyrimidine (anti-AP) monoclonal antibody was pur-
chased from Cosmo Bio Co. Ltd. (Tokyo, Japan), and
horseradish peroxidase (HRP)-conjugated goat anti-mouse
IgG and HRP-conjugated goat anti-rabbit IgG were from
Sigma Chemical Co. (St. Louis, MO, USA).
BSA/glc and BSA/gal in vitro as anti-protein glycation
screening models
The BSA/glc or BSA/gal models for protein glycation ex-
periments in vitro (Ahmad et al. 2007; Ledesma-Osuna
et al. 2008) were followed with some modifications. The
total 100 μl of reaction solution contained 20 μl of BSA
solution (2 mg/ml), 60 μl of 1M gal or glc solution, 10 μl
of PBS (10-fold dilutions in the final), and 10 μl of DMSO
or tested compounds (A, I, C and D, each 50 mM, and
5 mM in the final). The blank test contained BSA only, and
the control test contained BSA/gal or BSA/glc under the
same conditions. These mixtures were placed in a 37°C
water bath for the desired number of days (3, 6, 10, or 14
days for glycation experiments or 3, 5, or 7 days for anti-
glycation experiments with tested compound additions),
and then were stored at 4°C for further use. After that, a
24 μl of each reaction solution was mixed with 6 μl of
sample buffer (5-fold dilution) and heated at 100°C for
5 min. An aliquot of 15 μl was then added to each well of
10% sodium dodecyl sulfate-polyacrylamide for gel elec-
trophoresis. After electrophoresis, the gels were cut into 2
parts. One part was fixed with 12.5% trichloroacetic acid
for 30 min and then stained with Coomassie brilliant blue
G-250; the other part was equilibrated in Tris-glycine buf-
fer (pH 8.3) and transferred onto immobile polyvinylidene
difluoride (PVDF) membranes (Millipore, Bedford, MA,
USA) for immunostaining. The PVDF membranes were
blocked with 1% gelatin in NaCl/EDTA/Tris (NET) solu-
tion for 1 h at room temperature and incubated overnight
at 4°C. An anti-CML antibody was used at a 5000-fold
dilution. The PVDF membrane was washed 3 times for
10 min with PBS containing Tween-20 (PBST). Next,
HRP-conjugated secondary antibody solution (5000-fold
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the membrane was washed with 1× PBST. Immunoblots
were stained by using the HRP-hydrogen peroxide-
aminoethyl carbazole system. For quantifying CML forma-
tions in the BSA/glc or BSA/gal models, an enzyme-linked
immunosorbent assay (ELISA) was performed. A 100-μl
aliquot containing 5-μl of the reaction solution or 100-μl
of 10-fold diluted PBS was loaded into a high-binding
96-well microtiter plate (Nunc MaxiSorp, type F, Roskilde,
Denmark); the plate was covered with an adhesive strip
and incubated at 37°C for 2 h, washed thrice for 10
min each with 200 μl of PBST, and then blocked with
100 μl of NET solution at 37°C for 30 min. A 100-μl
anti-CML polyclonal antibody solution (5000-fold dilu-
tion in 0.25% gelatin in NET solution) was added and the
samples were incubated at 4°C overnight, followed by
washing of the plates thrice for 10 min each with 200 μl of
PBST. Next, 100 μl of HRP-conjugated goat anti-rabbit
IgG solution (5000-fold dilution in 0.25% gelatin in NET
solution) was added, and the samples were incubated at
37°C for 1 h; subsequently, the plate was washed again
using 200 μl of PBST. A staining solution was prepared by
dissolving 1 mg of 3,3′,5,5′-tetramethylbenzidine in 1 ml
of DMSO, followed by addition of 5 μl of 30% hydrogen
peroxide; the volume was increased to 10 ml with 50 mM
PB, pH 5.0. A 100-μl aliquot of staining solution was
added to the plate; this reaction was allowed to proceed in
the dark at 37°C for 30 min. The reaction was stopped by
adding 25 μl of 1 M HCl, and the absorbance at 450 nm
was measured by using an ELISA reader (TECAN Sunrise
microplate reader; Männedorf, Switzerland). For anti-
protein glycation in the presence of A, I, C, or D, the
relative CML formed index (%) was expressed and the
CML formation in the control was recognized as 100%.
BSA/MGO as models for anti-protein glycation in vitro
The BSA/MGO models for protein glycation experiments
in vitro (Wu and Yen 2005; Wu et al. 2011) were followed
with some modifications. The total 100-μl reaction solu-
tion contained 20 μl of BSA solution (2 mg/ml), 10 μl of
PBS (10-fold dilutions in the final), 10 μl of 10 mM or
50 mM MGO, 50 μl of tested compounds (A, I, C and
D, each 1 mM or 10 mM), and distilled water. The blank
test contained BSA only, and the control test contained
BSA/MGO under the same conditions. These mixtures
were placed in a 37°C water bath for the desired number
of days (2 or 3 days for glycation experiments or 3 days
for anti-glycation experiments with tested compound
additions), and then stored at 4°C for further use. After
that, an 8 μl of each reaction solution was mixed with 2 μl
of sample buffer (5-fold dilution) and was then heated
at 100°C for 5 min; an aliquot of 5 μl was added to each
well of 10% sodium dodecyl sulfate-polyacrylamide gel
in preparation for electrophoresis. After electrophoresis,the gels were cut into 2 parts; one was fixed with 12.5%
trichloroacetic acid for 30 min and then stained with
Coomassie brilliant blue G-250, while the other part was
equilibrated in Tris-glycine buffer (pH 8.3) and transferred
onto immobile PVDF membranes (Millipore, Bedford,
MA, USA) for immunostaining. An anti-AP monoclonal
antibody and HRP-conjugated secondary antibody solu-
tion were used at a 5000-fold dilution. Immunoblots were
detected using Western Chemiluminescent HRP Substrate
kits containing luminol reagents and peroxide solutions
(no. WBKL S0050; Immobilon™, Millipore). Each blot was
imaged using the Syngene GeneGnome5 imaging system
(Syngene, Cambridge, UK) equipped with the GeneSys/
GeneTools software (Syngene). For quantifying AP forma-
tions in the BSA/MGO models, an ELISA was performed.
A 100-μl aliquot containing 2-μl of the reaction solution
or 100-μl of 10-fold diluted PBS was loaded into a high-
binding 96-well microtiter plate (Nunc MaxiSorp, type F,
Roskilde, Denmark). The 100-μl anti-AP monoclonal anti-
body solution (5000-fold dilution in 0.25% gelatin in NET
solution) and 100 μl of HRP-conjugated goat anti-mouse
IgG solution (5000-fold dilution in 0.25% gelatin in NET
solution) were used for detections. The ELISA staining
procedure was the same as above-mentioned, and the
absorbance at 450 nm was measured by using an ELISA
reader (TECAN Sunrise microplate reader; Männedorf,
Switzerland). For anti-protein glycation in the presence
of A, I, C, or D, the relative AP formed index (%) was
expressed and the AP formation in the control (BSA/
MGO) was recognized as 100%.
Statistical analyses
The mean ± SD values were calculated from triplicate
measurements. The difference between the control and
the experimental group at the same treated time or the
saqme concentration was analyzed using Student’s t-test,
and the P-value of less than 0.05 (*), 0.01 (**), and 0.001
(***) were recognized as different significantly. The stat-
istical analysis was performed using the GraphPad Prism
Software 5.0.
Results and discussion
A and I were reported to have antioxidant activities
in vitro, and A also exhibited antihypertensive activities in
spontaneously hypertensive rat models (Chen et al. 2012).
In this study, A, I, and the constituents C and D, were
used to investigate the inhibitory activity against AGEs
formations in vitro detected by anti-CML using BSA/glc
and BSA/gal as models or by anti-AP using BSA/MGO
as models. Figure 1 shows the structure of A, I, C, and D.
The CML was reported to be the most thoroughly stud-
ied with respect to the chemical and biological properties
of AGE (Nagai et al. 2013). In the beginning, the protein
glycation formations were tested at different days (at 3, 6,
Figure 1 The structures of (A) acteoside, (B) isoacteoside, (C) caffeic acid, and (D) 3′,4′-dihydroxyphenylethanol used in the experiments.
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Figure 2(A) shows the protein stains; Figure 2(B) shows
the immune stains. Compared to the BSA only, at day
14 of incubation (the left lane), the protein band of
BSA (Figure 2(A)) was gradually faded after prolonged
incubation (at the 10- or 14-day reaction point), while
the CML formations in the same BSA protein band
position gradually increased (Figure 2(B)) as detectedFigure 2 The bovine serum albumin (BSA) glycation formations were
(glc) or BSA/galactose (gal) models. (A) The protein stains in SDS-PAGE
Nε-(carboxymethyl)lysine (anti-CML) antibody; (C) The ELISA method for CMby Western blotting using the anti-CML antibody. The
CML formations were accelerated in the BSA/gal
models more than in the BSA/glc models, and the
CML formations were clearly stained after the 6-day
incubation period in the BSA/gal models. However, the
14-day incubation in the BSA/glc models was required
for detection of CML formations. On the other hand,
the versatile ELISA method was developed for proteindetected at different days (3, 6, 10, and 14 days) in BSA/glucose
gels by Coomassie brilliant blue G-250; (B) The immune stains by anti-
L formations detected by anti-Nε-(carboxymethyl)lysine antibody.
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body in the BSA/glc or BSA/gal models as showed in
Figure 2(C). Compared to the BSA only, at 3-, 6-, 10-
and 14-day incubations (as the blank), the CML forma-
tions in BSA/glc or BSA/gal increased as the days of
incubation increased. The CML formations could be
detected by the ELISA method in the BSA/glc models
only at 3-day incubation. The number of CML forma-
tions (CML formed index) in the BSA/glc models after
14-day incubations were between those of the 3-day
and 6-day incubations of the BSA/gal models. The
CML formations in the ELISA data (Figure 2(C)) were
comparable to those of the immune stains (Figure 2(B))
in Western blotting. The D-glc or D-gal was reported to
react with proteins/peptides both in vitro and in vivo, as
well as with their metabolized intermediates such as
glyoxal or MGO, leading to AGE formations through
nonenzymatic glycation (Song et al. 1999; Parameshwaran
et al. 2010; Tsai et al. 2011). The reaction rate of D-gal is
approximately 4.7-fold of the reactivity of D-glc toward
hemoglobin in vitro (Burn and Higgins 1981). Therefore,
A, I, C and D were used to evaluate the effects on anti-
protein glycation.
Figure 3 shows the anti-CML formations of A, I, C
and D each being at 5 mM in the BSA/glc models
(Figure 3(A)) and the BSA/gal models (Figure 3(B))
after 3-day, 5-day, and 7-day incubations by the ELISA
method. In the BSA/glc models, it was found that A or
I additions showed no significant difference (P > 0.05)
in CML formations compared to the control. However,
the constituent of C or D showed a significant difference
(P < 0.05 or P < 0.01) in CML formations compared to
the control after 3-day, 5-day and 7-day incubations
(Figure 3(A)). In the BSA/gal models, A, I, C and D addi-
tions showed significant differences (P < 0.01 or P < 0.001)
in CML formations compared to the control after 3-day
and 5-day incubations, but not after 7-day incubations
(Figure 3(B)). This meant that the anti-protein glycation
activity of A or I was originally from C or D. Fujiwara
et al. (2008) reported that natural compounds, including:
acteoside, quercetin, and quercetin 3-sambubioside, could
stimulate CML formations, and sophoradiol and lupeol
could lower CML formations detected by the anti-CML
antibody using the ELISA method in BSA (2 mg/ml) and
ribose (33 mM) in PBS at 37°C for 7-day incubations. Our
present results of A or I with anti-CML formations at
BSA/gal models differed from those reported by Fujiwara
et al. (2008); the different glycation systems (BSA/gal vs.
BSA/ribose) and different incubation periods (3-day or
5-day vs. 7-day) might be reasons for these differences.
Wu and Yen (2005) reported that flavonoids, including:
luteolin, quercetin, rutin, etc., could lower AGE forma-
tions detected by glycated protein fluorescence (Ex 330
nm and Em 410 nm) in BSA (50 mg/ml) and glc (0.8 M)in 1.5 M PB (pH 7.4) at 37°C for 7-day incubations, and
they proposed that the hydroxyl group at the C-3′ position
of flavonoid and/or antioxidant properties contributed to
the inhibitory activities against AGE formations. The A or
I and its constituents of C and D had one hydroxyl group
in catechol (3,4-dihydroxyphenol) moiety, and the A and I
were reported to have antioxidant activities (Chen et al.
2012). This was the same as the proposal of Wu and Yen
(2005) for anti-protein glycation. Nagai et al. (2013)
reviewed and proposed that a molecule with the catechol
group (such as gallic acid, quercetin, isoquercetin, luteolin
7-O-glucoside and acteoside) under high concentrations
(such as 1 mM) may enhance CML formations, and low
concentrations (such as 0.01 mM) may attenuate CML
formations. However, these proposals were not followed
by a series of structure-activity relationship investigations.
Figure 4 shows the anti-AP formations of A, I, C and D
in the BSA/MGO models. Padayatti et al. (2001) reported
that MGO could rapidly interact with Arg protein resi-
dues, but not with Lys protein residues, to generate AP
formations, which were at high levels in brunescent cata-
ractous lenses, a diabetic complication. In the beginning,
the AP formations were detected by the ELISA method
in different MGO concentrations (1 or 5 mM) for 2- or
3-day incubations (Figure 4(A)). It was found that
higher MGO concentrations may increase higher levels
of AP productions (AP formed index A450 nm) in BSA/
MGO models under the same incubation days. There-
fore, BSA/5 mM MGO for 3-day incubations were selected
for further investigation. It was found that A, I, C and D at
0.5 mM or 5 mM could lower AP formations (Figure 4(B)),
and showed significant differences (P < 0.001) compared
to the control (BSA/5 mM MGO for 3-day incubations)
using the ELISA method and detection by the anti-AP
antibody. The use of Western blot revealed the BSA
glycations (BSA/5 mM MGO for 3-day incubations)
detected by AP antibodies. It was found that the A, I, C
and D at 5 mM showed clear reductions of AP forma-
tions in BSA positions, and C and D at 0.5 mM also
showed anti-AP formation activities (Figure 4(C)). The
proanthocyanidins from cinnamon bark were reported
to have scavenging activities against MGO to form
MGO-procyanidin adducts and then prevented AGE
formations (Peng et al. 2008).
From the results shown in Figures 3 and 4, we proposed
that the anti-protein glycation activities of A and I may
result from the constituents of C or D. It was reported
that C exhibited antioxidant activity (Chen and Ho
1997) and anti-glycation activity against BSA/MGO
models (Gugliucci et al. 2009). The constituent D was
reported to have protective roles against hydrogen
peroxide–induced cell cytotoxicity (Manna et al. 1997).
The antioxidant activities of C and D may explain in





































































































Figure 3 Effects of acteoside (A), isoacteoside (I), caffeic acid (C), and 3′,4′-dihydroxyphenylethanol (D) on anti-CML formatiopns in
different incubation days (3, 5, and 7 days) at (A) BSA/glc modes or (B) BSA/gal models. Each tested sample was 5 mM in the final
concentration. The mean ± SD values were calculated from triplicate measurements. The difference between the control and the experimental
group at the same treated time was analyzed using Student’s t-test, and the P-value of less than 0.05 (*), 0.01 (**), and 0.001 (***) were
recognized as different significantly.
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proglycation effects (or pro-oxidant activity detected
by electron spin resonances), which were enhanced
by metal ions (such as Fe2+ and Cu2+) and abolished by
EDTA, reduced glutathione, or α-lipoic acid in BSA/
MGO models. The present results were similar to those
of Gugliucci et al. (2009) and different from those of
Wu et al. (2011). This might be due to the detection
method used (antibody detection vs. protein cross-linking in SDS-PGAE gels) and the number of incubation
days (3-day vs. 7-day). The uses of antibody to detect the
AGE formations in the present results are more specific
than in other reported results detected by glycated protein
fluorescence (Ex 330 nm and Em 410 nm). However, the
immune stain used in the present research cannot cover
all forms of chemically identified AGE. It is noted that the
anti-glycation activity does not show a positive correlation
with the diabetic treatments (Nagai et al. 2013). Therefore,
Figure 4 Effects of acteoside (A), isoacteoside (I), caffeic acid (C), and 3′,4′-dihydroxyphenylethanol (D) on anti-argpyrimidine (anti-AP)
formatiopns in different incubation days (2 or 3 days) at BSA/methylglyoxal (MGO) models. (A) The AP formations in BSA under different MGO
concentrations (1 or 5 mM in the final concentrations) for 2 or 3 days using ELISA methods detected by anti-argpyrimidine (anti-AP) antibody;
(B) Effects of 0.5 or 5 mM concentrations of A, I, C, and D on anti-AP formations for 3-day in BSA/MGO (5 mM) models detected by ELISA methods;
(C) The immune stains on anti-AP formations for 3-day in BSA/MGO (5 mM) models detected by anti-AP antibody. The mean ± SD values were
calculated from triplicate measurements. The difference between the control and the experimental group at the same concentration was analyzed
using Student’s t-test, and the P-value of less than 0.05 (*), 0.01 (**), and 0.001 (***) were recognized as different significantly.
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animal models should be performed to clarify the effects
of the natural products of A, I, C and D on anti-diabetic
complications and/or anti-diabetes treatment.Conclusions
In conclusion, A and I together with its consittuents, C
and D, exhibited anti-protein glycation activities in
different model systems in vitro. The results suggest the
Liu et al. Botanical Studies 2013, 54:6 Page 8 of 9
http://www.as-botanicalstudies.com/content/54/1/6potential anti-glycation activities of A and I in vitro may
apply to cell models in higher glucose concentrations or
diabetic animal models and need further investigations.
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